Overview of Dr. Rudin
Dr. Charles Rudin is an oncologist in New York, NY and is Chief of Thoracic Oncology at Memorial Sloan Kettering Cancer Center. He received his medical degree and PhD from University of Chicago Pritzker School of Medicine. He specializes in lung cancer research and clinical care.
Office
530 East 74th Street
New York, NY 10021
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 1995 - 1998
- University of ChicagoResidency, Internal Medicine, 1993 - 1995
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1993
Certifications & Licensure
- FL State Medical License 2022 - Present
- NY State Medical License 2013 - 2027
- NJ State Medical License 2018 - 2025
- MD State Medical License 2003 - 2013
- IL State Medical License 1993 - 2005
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2010
Clinical Trials
- Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2000 Apr 01
- Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2001 Apr 01
- Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors Start of enrollment: 2001 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsAutomated real-world data integration improves cancer outcome prediction.Justin Jee, Christopher Fong, Karl Pichotta, Thinh Ngoc Tran, Anisha Luthra
Nature. 2024-12-01 - Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies.Michael V Gormally, Monica F Chen, Anne Marie Noronha, Kristalla Panageas, Maggie Reynolds
JAMA Oncology. 2024-11-27 - Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer.Abbie S Ireland, Sarah B Hawgood, Daniel A Xie, Margaret W Barbier, Scarlett Lucas-Randolph
Biorxiv. 2024-11-15
Journal Articles
- PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung CancersG J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology
Other
- Head and neck squamous cell carcinogenesis: Molecular and genetic alterationsRudin CM, Marur S
http://www.uptodate.com/contents/head-and-neck-squamous-cell-carcinogenesis-molecular-and-genetic-al
UpToDate, Wolters Kluwer Health - 2012-04-09 - Chemoprevention in oral dysplasia and head and neck cancerRudin CM, Marur S
http://www.uptodate.com/contents/chemoprevention-in-oral-dysplasia-and-head-and-neck-cancer
UpToDate, Wolters Kluwer Health - 2012-05-31
Press Mentions
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024October 24th, 2024
- MSK Researchers Discover New Type of SCLCSeptember 18th, 2024
- New, Rare Type of Small Cell Lung Cancer IdentifiedSeptember 11th, 2024
- Join now to see all
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS North Carolina BlueOptions PPO
Blue Shield California PPO
CareFirst BCBS Maryland POS
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMOCIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: